With ICH E6 (R3) and trial quality taking center stage at this week’s #SCOPESummit, our latest blog explores how proportionality and risk-based strategies under the new guidance are redefining sponsor responsibilities. In Raising the Bar for E6 (R3): Why Quality and Training Will Define Your Success (https://bit.ly/3PRRIK2), we examine how these principles are raising the stakes and making proactive, quality-by-design approaches essential—especially when it comes to modern training. Quality can no longer be an afterthought; it must be intentionally embedded into every aspect of a trial, beginning with how we prepare our sites and study teams. If you are attending the SCOPE Summit this week, let’s connect! We'd love to discuss the implications of R3 and how ArcheMedX, Inc. and the Ready platform can equip your teams to meet these new standards with the confidence to deliver higher-quality trials at lower cost. We look forward to continuing the conversation—both online and in person at SCOPE! #ClinicalTrials #E6R3 #RiskBasedApproach #ModernTraining
